Clinical trials
Lupus clinical trials
Below are recruiting lupus clinical trials, each written for real people, not researchers. We’re tracking 336 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07330245Recruiting
Study of anifrolumab for lupus patients needing treatment
This study looks at how well anifrolumab works for people with systemic lupus erythematosus (SLE) who are starting it for the first time. It aims to see if patients can achieve a low disease activity state (LLDAS5) after treatment.
Monserrato, CAAges Any age - NCT07331272RecruitingPhase 1
CAR T-cells for lupus and myositis
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
Bengbu, AnhuiAges 18–70 - NCT07339332RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This study tests whether a new CAR-T cell treatment (called CT1195E) can help people with lupus that hasn't improved with standard medicines. CAR-T cells are specially trained immune cells that seek out and destroy certain faulty immune cells, which may reduce lupus symptoms. The trial is for people with moderate to severe active lupus affecting organs like the kidneys, heart, or blood system.
Wuhan, HubeiAges 18–65 - NCT07679776Enrolling by invitation
Study on early vision changes in lupus patients
This study looks at whether people with systemic lupus erythematosus (SLE) have early signs of vision problems. Eye tests will be used to check how well you see and if there are any hidden issues in your eyes.
Hefei, AnhuiAges Any age - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT07348055RecruitingPhase 1/Phase 2
A study of GR1803 for lupus
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
Wuhan, HubeiAges 18–60 - NCT07397728Recruiting
TREX1 gene changes in lupus with skin rashes
This trial tests for a specific gene change (in the TREX1 gene) in people with lupus, especially those who have lupus-related skin rashes. It aims to understand how this gene may affect the disease.
Qina, South ValleyAges 18–60 - NCT00001372Recruiting
Understanding Lupus: Research Study at NIH
This research study aims to better understand systemic lupus erythematosus (SLE), an autoimmune disease where the body's immune system attacks its own tissues. Researchers will evaluate patients with lupus, study genetic factors, and perform optional imaging tests to learn how the disease affects blood vessels and the heart.
Bethesda, MarylandAges 3–120 - NCT01510067Recruiting
Study of skin lupus types and how severe they are
This study looks at adults with cutaneous lupus (skin lupus) and/or systemic lupus (a whole-body autoimmune condition) to understand how common it is and how severe the skin symptoms become. It may help researchers better describe different skin lupus forms and their impact.
Philadelphia, PennsylvaniaAges 18 years+ - NCT00198068Recruiting
Study pregnancy outcomes in lupus and antiphospholipid syndrome
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
Chicago, IllinoisAges 18–45 - NCT00756769Recruiting
Gullah community study for lupus symptoms and risk factors
This study looks at lupus in people from the Gullah community in South Carolina, including people with lupus and healthy comparison participants. It may help researchers better understand who is at risk and how lupus shows up in this community.
Charleston, South CarolinaAges 2 years+ - NCT02954939Recruiting
Test medicines to change immune cells in lupus kidney flare
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
Hong KongAges 18–80 - NCT06314282Recruiting
Lupus study tracking real-world results with anifrolumab
This study looks at how well anifrolumab works for people with lupus in everyday medical care, not just in a research lab. It may help you if your doctor has decided to prescribe anifrolumab for the first time.
Buenos AiresAges 18 years+ - NCT07405970RecruitingPhase 3
Testing MIL62 for active lupus
This trial tests an investigational drug called MIL62 for people with systemic lupus erythematosus (SLE) that is still active despite standard treatments. The goal is to see if MIL62 can better control disease activity.
BeijingAges 18–80 - NCT07425730Recruiting
Heart problems in childhood lupus study
This study looks at early heart function problems in children with lupus to find those at risk for severe disease. It may help doctors identify and treat severe lupus sooner.
Shanghai, Shanghai MunicipalityAges 7–17 - NCT07440537RecruitingPhase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
Hefei, AnhuiAges 18–75 - NCT07444307RecruitingPhase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
Hefei, AnhuiAges 18–65 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT06946485RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy called CAR-T cells that target a protein called CD70 on immune cells. The goal is to see if it can help people with active lupus that has not improved with standard treatments.
Nanjing, JiangsuAges 18–65 - NCT06535412RecruitingPhase 1/Phase 2
Study of IMC-002 for active lupus
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
BeijingAges 18–65 - NCT07666711Recruiting
Kidney biomarker study for lupus patients
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
Oslo, OsloAges 18 years+ - NCT07575347Recruiting
Gum Disease and Rare Kidney Disorders Study
This study explores whether people with certain rare kidney diseases or chronic kidney problems have more gum disease than others. Researchers will examine your teeth and gums to understand the connection and help improve care for people with kidney conditions.
BucharestAges 18 years+ - NCT07617740RecruitingEarly Phase 1
IASO207 cell therapy for treatment-resistant lupus
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
BeijingAges 18–75 - NCT07657793RecruitingPhase 2/Phase 3
Sirolimus for Lupus-Related Low Platelets
This trial tests sirolimus, an immune-system-calming medicine, for people with lupus who also have very low platelet counts (ITP). It may help reduce bleeding risk and improve platelet numbers.
Beijing, Beijing MunicipalityAges 18–65
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus?
- Yes. Clin2 currently lists 336 recruiting lupus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.